Recent Performance Snapshot

Medpace Holdings (MEDP) has attracted attention after recent share price moves, with the stock up about 2.5% over the past day, 5.9% over the past week, and 8.1% over the past month.

That short term 1 day share price return of 2.5% and 1 month share price return of 8.1% sit against a 90 day share price decline of 17.1% and a 1 year total shareholder return of 83.4%. This suggests momentum has picked up again after a weaker recent quarter.

If Medpace has caught your eye, this can be a moment to scan related opportunities in healthcare and biotech, starting with 37 healthcare AI stocks.

With Medpace trading around US$508.52, slightly above the average analyst price target and yet sitting on an intrinsic value discount, the key question is simple: is this a fresh entry point or is the market already pricing in future growth?

Most Popular Narrative: 1.7% Overvalued

With Medpace at about $508.52 versus a narrative fair value of roughly $500.08, the current price sits slightly above that widely followed view, putting the underlying assumptions in the spotlight.

The rapid revenue acceleration in 2025 is heavily influenced by a therapeutic mix shift toward faster-burning studies (such as metabolic trials) with higher reimbursable costs, increasing "pass-through" revenue that is less margin-accretive. This could result in lower underlying revenue and EBITDA growth once this project mix normalizes. Funding for many clients, especially small biotech, remains fragile, with low cancellations having driven recent upside. Should the improved funding or lower cancellations reverse (as seen in previous quarters), revenue and earnings growth could sharply decelerate, indicating that the current growth levels may not be sustainable.

Curious what earnings path, margin profile, and valuation multiple need to line up for that fair value to make sense? The narrative leans on a carefully paced revenue glide, firmer profitability, and a future P/E reset that still assumes healthy confidence in Medpace's long term cash generation.

Result: Fair Value of $500.08 (OVERVALUED)

However, this view still relies on assumptions that biotech funding remains stable and that faster-burning, pass-through-heavy contracts do not unsettle margins or bookings.

Another Angle: DCF Points to Undervaluation

The narrative fair value of about $500.08 suggests Medpace is 1.7% overvalued at $508.52, yet the SWS DCF model points the other way, with a future cash flow value of $568.51 and the shares trading 10.6% below that mark. Which lens do you trust more for a long term view?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Medpace Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 61 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals across fair value models, it is worth checking the underlying data yourself and moving quickly to shape your own view, starting with the 3 key rewards.

Looking for more investment ideas?

If Medpace is only one part of your watchlist, this is a good moment to widen the net and compare it with other clearly defined opportunities.

• Spot potential value candidates early by scanning 61 high quality undervalued stocks that pair solid fundamentals with prices the market may not fully reflect.
• Strengthen the quality of your watchlist by filtering for companies in the solid balance sheet and fundamentals stocks screener (40 results) that can better handle business shocks.
• Hunt for overlooked opportunities with the screener containing 24 high quality undiscovered gems before they are widely discussed and harder to access on favorable terms.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.